Treatment of demyelinating diseases

Abstract

The present invention relates generally to methods of using nalfurafine for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.

1 .- 26 . (canceled) 
     
     
         27 . A method of treating a demyelinating disease in a subject, comprising administering a pharmaceutical composition comprising nalfurafine to the subject. 
     
     
         28 . The method according to  claim 27 , wherein the pharmaceutical composition is administered to the subject for a period of (i) at least 7 days, (ii) at least 14 days, or (iii) at least one month. 
     
     
         29 . The method according to  claim 27 , wherein the pharmaceutical composition is administered to the subject to obtain a dosage of about 0.1 to about 10.0 μg nalfurafine daily. 
     
     
         30 . The method according to  claim 27 , wherein the pharmaceutical composition is administered to the subject to obtain a dosage of nalfurafine which is equivalent to a dose of about 0.003 to about 0.3 mg/kg of nalfurafine in mice. 
     
     
         31 . The method according to  claim 27 , wherein the demyelinating disease is selected from the group consisting of multiple sclerosis (MS), optic neuritis, Devic's disease, inflammatory demyelinating diseases, central nervous system neuropathies, myelopathies,  Tabes dorsalis , leukoencephalopathies, leukodystrophies, Guillain-Barre syndrome and its chronic counterpart, chronic inflammatory demyelinating polyneuropathy, anti-MAG (myelin-associated glycoprotein) peripheral neuropathy, Charcot Marie Tooth (CMT) disease, copper deficiency, progressive inflammatory neuropathy, and any combination thereof. 
     
     
         32 . The method according to  claim 31 , wherein administration of the pharmaceutical composition to the subject results in one or more clinical outcomes selected from the group consisting of:
 a decrease or delay in nerve cell demyelination;   a healing of damaged nerve tissue;   an increase in remyelination of demyelinated nerves in the subject's central nervous system;   neuroprotection;   protection of damaged nerve tissue from further disease activity;   promotion of neuronal outgrowth in the subject's central nervous system; and   an improvement in nerve function.   
     
     
         33 . The method according to  claim 31 , wherein administration of the pharmaceutical composition to the subject results in one or more clinical outcomes selected from the group consisting of:
 a decrease in demyelinating disease progression;   a decrease in demyelinating disease severity;   a decrease in frequency or severity of relapsing demyelinating disease attacks;   a decrease in disability caused by demyelinating disease;   a decrease in demyelinating disease clinical symptoms;   a decrease in paralysis;   an improvement in balance or coordination; and   an enhanced rate of remission.   
     
     
         34 . The method according to  claim 31 , wherein administration of the pharmaceutical composition to the subject results in a reduction of one or more clinical symptoms selected from the group consisting of: loss of sensitivity, muscle weakness, impaired walking, impaired hand function, pronounced reflexes, muscle spasms, difficulty in moving, ataxia, spasticity, problems with speech or swallowing, visual problems, fatigue, acute or chronic pain, facial pain, incontinence, reduced cognitive ability, depression, anxiety, sexual dysfunction, Uhthoff s phenomenon, and Lhermitte's sign. 
     
     
         35 . A method of increasing remyelination of nerves in a subject, comprising administering a pharmaceutical composition comprising nalfurafine to the subject. 
     
     
         36 . The method according to  claim 35 , wherein the pharmaceutical composition is administered to the subject for a period of (i) at least 7 days, (ii) at least 14 days, or (iii) at least one month 
     
     
         37 . The method according to  claim 35 , wherein the pharmaceutical composition is administered to the subject to obtain a dosage of about 0.1 to about 10.0 μg nalfurafine daily. 
     
     
         38 . The method according to  claim 35 , wherein the pharmaceutical composition is administered to the subject to obtain a dosage of nalfurafine which is equivalent to a dose of about 0.003 to about 0.3 mg/kg of nalfurafine in mice. 
     
     
         39 . The method according to  claim 35 , wherein the subject has one or more symptoms of a demyelinating disease selected from the group consisting of multiple sclerosis (MS), optic neuritis, Devic's disease, inflammatory demyelinating diseases, central nervous system neuropathies, myelopathies,  Tabes dorsalis , leukoencephalopathies, leukodystrophies, Guillain-Barre syndrome and its chronic counterpart, chronic inflammatory demyelinating polyneuropathy, anti-MAG (myelin-associated glycoprotein) peripheral neuropathy, Charcot Marie Tooth (CMT) disease, copper deficiency, progressive inflammatory neuropathy, and any combination thereof. 
     
     
         40 . The method according to  claim 39 , wherein administration of the pharmaceutical composition to the subject results in one or more clinical outcomes selected from the group consisting of:
 a decrease or delay in nerve cell demyelination;   a healing of damaged nerve tissue;   an increase in remyelination of demyelinated nerves in the subject's central nervous system;   neuroprotection;   protection of damaged nerve tissue from further disease activity;   promotion of neuronal outgrowth in the subject's central nervous system; and   an improvement in nerve function.   
     
     
         41 . The method according to  claim 39 , wherein administration of the pharmaceutical composition to the subject results in one or more clinical outcomes selected from the group consisting of:
 a decrease in demyelinating disease progression;   a decrease in demyelinating disease severity;   a decrease in frequency or severity of relapsing demyelinating disease attacks;   a decrease in disability caused by demyelinating disease;   a decrease in demyelinating disease clinical symptoms;   a decrease in paralysis;   an improvement in balance or coordination; and   an enhanced rate of remission.   
     
     
         42 . The method according to  claim 39 , wherein administration of the pharmaceutical composition to the subject results in a reduction of one or more clinical symptoms selected from the group consisting of: loss of sensitivity, muscle weakness, impaired walking, impaired hand function, pronounced reflexes, muscle spasms, difficulty in moving, ataxia, spasticity, problems with speech or swallowing, visual problems, fatigue, acute or chronic pain, facial pain, incontinence, reduced cognitive ability, depression, anxiety, sexual dysfunction, Uhthoff s phenomenon, and Lhermitte's sign. 
     
     
         43 . A method of attenuating demyelination of nerves in a subject, comprising administering a pharmaceutical composition comprising nalfurafine to the subject. 
     
     
         44 . The method according to  claim 43 , wherein the pharmaceutical composition is administered to the subject for a period of (i) at least 7 days, (ii) at least 14 days, or (iii) at least one month. 
     
     
         45 . The method according to  claim 43 , wherein the pharmaceutical composition is administered to the subject to obtain a dosage of about 0.1 to about 10.0 μg nalfurafine daily. 
     
     
         46 . The method according to  claim 44 , wherein the pharmaceutical composition is administered to the subject to obtain a dosage of nalfurafine which is equivalent to a dose of about 0.003 to about 0.3 mg/kg of nalfurafine in mice. 
     
     
         47 . The method according to  claim 43 , wherein the subject has one or more symptoms of a demyelinating disease selected from the group consisting of multiple sclerosis (MS), optic neuritis, Devic's disease, inflammatory demyelinating diseases, central nervous system neuropathies, myelopathies,  Tabes dorsalis , leukoencephalopathies, leukodystrophies, Guillain-Barre syndrome and its chronic counterpart, chronic inflammatory demyelinating polyneuropathy, anti-MAG (myelin-associated glycoprotein) peripheral neuropathy, Charcot Marie Tooth (CMT) disease, copper deficiency, progressive inflammatory neuropathy, and any combination thereof. 
     
     
         48 . The method according to  claim 46 , wherein administration of the pharmaceutical composition to the subject results in one or more clinical outcomes selected from the group consisting of:
 a decrease or delay in nerve cell demyelination;   a healing of damaged nerve tissue;   an increase in remyelination of demyelinated nerves in the subject's central nervous system;   neuroprotection;   protection of damaged nerve tissue from further disease activity;   promotion of neuronal outgrowth in the subject's central nervous system; and   an improvement in nerve function.   
     
     
         49 . The method according to  claim 46 , wherein administration of the pharmaceutical composition to the subject results in one or more clinical outcomes selected from the group consisting of:
 a decrease in demyelinating disease progression;   a decrease in demyelinating disease severity;   a decrease in frequency or severity of relapsing demyelinating disease attacks;   a decrease in disability caused by demyelinating disease;   a decrease in demyelinating disease clinical symptoms;   a decrease in paralysis;   an improvement in balance or coordination; and   an enhanced rate of remission.   
     
     
         50 . The method according to  claim 46 , wherein administration of the pharmaceutical composition to the subject results in a reduction of one or more clinical symptoms selected from the group consisting of: loss of sensitivity, muscle weakness, impaired walking, impaired hand function, pronounced reflexes, muscle spasms, difficulty in moving, ataxia, spasticity, problems with speech or swallowing, visual problems, fatigue, acute or chronic pain, facial pain, incontinence, reduced cognitive ability, depression, anxiety, sexual dysfunction, Uhthoff s phenomenon, and Lhermitte's sign.